| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4251375 | Seminars in Nuclear Medicine | 2010 | 10 Pages |
Abstract
The diphosphonate bone scan is ideally suited to assess many global, focal or multifocal metabolic bone disorders and there remains a role for conventional bone scintigraphy in metabolic bone disorders at diagnosis, investigation of complications, and treatment response assessment. In contrast, the role of bone scintigraphy in the evaluation of primary malignant bone tumors has reduced with the improvement of morphologic imaging, such as computed tomography and magnetic resonance imaging. However, an increasing role for 18F-fluorodeoxyglucose positron emission tomography and positron emission tomography/computed tomography is emerging as a functional assessment at diagnosis, staging, and neoadjuvant treatment response assessment.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Gary J.R. Cook, Gopinath Gnanasegaran, Sue Chua,